Recher, ChristianRoellig, ChristophBerard, EmilieBertoli, SarahDumas, Pierre-YvesTavitian, SuzanneKramer, MichaelServe, HubertBornhaeuser, MartinPlatzbecker, UweMueller-Tidow, CarstenBaldus, Claudia D.Martinez-Cuadron, DavidSerrano, JosefinaMartinez-Sanchez, PilarRodriguez Arboli, EduardoGil, CristinaBergua, JuanBernal, Teresade la Fuente Burguera, AdolfoDelabesse, EricBidet, AudreyPigneux, ArnaudMontesinos, Pau2025-01-072025-01-072021-11-130887-6924https://hdl.handle.net/10668/25507The outcome of acute myeloid leukemia patients aged 70 years or older is poor. Defining the best treatment option remains controversial especially when choosing between intensive chemotherapy and hypomethylating agents. We set up a multicentric European database collecting data of 3 700 newly diagnosed acute myeloid leukemia patients >= 70 years. The primary objective was to compare overall survival in patients selected for intensive chemotherapy (n = 1199) or hypomethylating agents (n = 1073). With a median follow-up of 49.5 months, the median overall survival was 10.9 (95% CI: 9.7-11.6) and 9.2 months (95% CI: 8.3-10.2) with chemotherapy and hypomethylating agents, respectively. Complete remission or complete remission with incomplete hematologic recovery was 56.1% and 19.7% with chemotherapy and hypomethylating agents, respectively (P = 70 years. The primary objective was to compare overall survival in patients selected for intensive chemotherapy (n = 1199) or hypomethylating agents (n = 1073). With a median follow-up of 49.5 months, the median overall survival was 10.9 (95% CI: 9.7-11.6) and 9.2 months (95% CI: 8.3-10.2) with chemotherapy and hypomethylating agents, respectively. Complete remission or complete remission with incomplete hematologic recovery was 56.1% and 19.7% with chemotherapy and hypomethylating agents, respectively (PenAttribution 4.0 Internationalhttp://creativecommons.org/licenses/by/4.0/Acute myeloid-leukemiaNewly-diagnosed amlEpigenetic therapyElderly-patientsEarly deathAzacitidineManagementVenetoclaxRegimensCareresearch article34775483open access10.1038/s41375-021-01425-91476-5551https://www.nature.com/articles/s41375-021-01425-9.pdf718063500001